Diligent use of MedDRA terminology and preferred term selection in safety reports of clinical trials
Curr Opin Oncol
.
2024 Sep 1;36(5):418-420.
doi: 10.1097/CCO.0000000000001056.
Epub 2024 Aug 8.
Authors
Martin F Fey
1
,
Seamus O'Reilly
2
,
Ahmad H Awada
3
,
John Crowley
4
,
Karen A Gelmon
5
Affiliations
1
Former Chairman of the Department of Medical Oncology, Inselspital and University of Bern, Bern, Switzerland.
2
Consultant Medical Oncologist, University College Cork, Cork, Ireland.
3
Medical Oncologist, Institut Jules Bordet, Université Libre de Bruxelles, Bruxelles, Belgium.
4
CRAB Cancer Research and Biostatistics, Seattle, Washington, USA.
5
University of British Columbia Faculty of Medicine, 2775 Laurel Street, Vancouver, British Columbia, Canada.
PMID:
39106404
DOI:
10.1097/CCO.0000000000001056
No abstract available
Publication types
Editorial
MeSH terms
Adverse Drug Reaction Reporting Systems / standards
Clinical Trials as Topic*
Humans
Terminology as Topic*